To further determine whether Lenvatinib resistance induced by DUSP4 deficiency was dependent on the activation of MAPK/ERK pathway, we used a MEK1/2 inhibitor, Selumetinib, to block the MAPK/ERK pathway in LR HCC cells. This evidence concerns the gene MAP2K1 and hepatocellular carcinoma.